Home › Funds › EVENTIDE ASSET MANAGEMENT, LLC › RPRX

EVENTIDE ASSET MANAGEMENT, LLC position in RPRX

ROYALTY PHARMA PLC · Health Care

EVENTIDE ASSET MANAGEMENT, LLC reported holding 1,518,893 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$88.6M, representing 1.24% of its reported portfolio and ranking #16 among its reported holdings. EVENTIDE ASSET MANAGEMENT, LLC has disclosed RPRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.52M sh
Reported value held$88.60M
Portfolio Weight1.24%
First reportedQ3 2023
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How EVENTIDE ASSET MANAGEMENT, LLC's RPRX position evolved

EVENTIDE ASSET MANAGEMENT, LLC first disclosed a stake in RPRX in Q3 2023 at 1,004,146 shares (US$27.3M). The position peaked in Q3 2026 at 1,518,893 shares, worth US$88.6M. Across 13 filings, EVENTIDE ASSET MANAGEMENT, LLC increased the stake 10 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,518,893 shares valued at US$88.6M — an increase of 138,632 shares quarter over quarter.. Notable position changes include a 47% trim in Q4 2023 (shares rose 8% over the following quarter), a 29% increase in Q1 2024 (shares fell 13% over the following quarter), a 41% increase in Q4 2025 (shares rose 24% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.00M $27.25M New
Q4 2023 533.98K $15.00M Reduce
Q1 2024 690.69K $20.98M Add
Q2 2024 749.63K $19.77M Add
Q3 2024 772.62K $21.86M Add
Q4 2024 823.39K $20.99M Add
Q1 2025 879.81K $27.41M Add
Q2 2025 921.64K $33.44M Add
Q3 2025 916.49K $32.33M Reduce
Q4 2025 1.30M $50.18M Add
Q1 2026 1.31M $62.60M Add
Q2 2026 1.38M $77.67M Add
Q3 2026 1.52M $88.60M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 46 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has EVENTIDE ASSET MANAGEMENT, LLC held RPRX?

EVENTIDE ASSET MANAGEMENT, LLC has disclosed RPRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is EVENTIDE ASSET MANAGEMENT, LLC's current position in RPRX?

As of Q3 2026, EVENTIDE ASSET MANAGEMENT, LLC holds 1.52M shares of RPRX (ROYALTY PHARMA PLC), valued at $88.60M, representing 1.24% of its reported portfolio and ranking #16.

Has EVENTIDE ASSET MANAGEMENT, LLC been buying or selling RPRX?

In the latest 13F filing (Q3 2026), EVENTIDE ASSET MANAGEMENT, LLC increased its position in RPRX. The position peaked in Q3 2026 at 1.52M shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.